Welcome Back NVD/ex-GSK Vaccine Peeps!

Sucks to be you!

 

Hope you guys are good at cheating on tests and taking your manager on a milk run cause that what we do at Gsk!

 

Trying to figure this out - we paid $ 7 Billion for the Novartis vaccine business unit! Has anyone ask why? Global market for menningicoccal is about $800 million annually of which Sanofi has about $600 million of that. So best case currently is Menveo is $ 200 million. The math doesn't add up. In addition, not the best source but here is an article from Fierce Pharma saying that Merck was prepared to pay $ 1 billion for the Novartis vaccine unit in February - wow by waiting for GSK they make an extra $ 6 billion! Is the share holder having one pulled over on them?

Buzz: Novartis mulls selling its vaccine unit as swap deal with Merck stalls

February 5, 2014 | By Nick Paul Taylor
SHARE

TOOLS
Comment
Print
Contact Author
Reprint
Last week Novartis' ($NVS) vaccine unit posted yet another operating loss, extending its streak in the red to four years. Yet despite its well-known, long-term problems, suitors are reportedly circling the unit, with the potential of Bexsero and Menveo likely to be a factor attracting potential buyers.


Joe Jimenez
News of interest in an outright buyout of the vaccine unit comes weeks after Bloomberg reported that Novartis was trying to arrange a swap deal with Merck ($MRK). Talks with Merck are continuing, the publication reports, but the companies have yet to agree on a valuation of the assets. In light of these difficulties, Novartis is reportedly looking into alternatives, including selling the vaccine business separately for $1 billion.

Although the buzz suggests the likelihood of an asset swap is fading, it is only a week since Novartis said anything is possible. "We want to build leading businesses at Novartis, and if that means that we're going to have to assume different or unconventional structures, or ways of thinking about the businesses differently, we're going to do that. So I wouldn't take anything off the table today," Novartis CEO Joe Jimenez said during last week's conference call to discuss fourth quarter results.



Read more: Buzz: Novartis mulls selling its vaccine unit as swap deal with Merck stalls - FierceVaccines http://www.fiercevaccines.com/story/buzz-novartis-mulls-selling-its-vaccine-unit-swap-deal-merck-stalls/2014-02-05#ixzz2ze8V6V3i
Subscribe at FierceVaccines

 

You know why we bought vaccines from Novartis? I don't know either. We've got a bunch of dumbass libtards running our company and spending our hard earned profits like US tax dollars. The HMS Dimwitty is sinking for sure!

 

Those poor bastards have to return. They thought they escaped.